Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Praluent Panel To Focus On Indication Breadth Absent CV Outcomes Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA briefing documents for June 9 advisory committee review of Sanofi/Regeneron's alirocumab reflect concern that PCSK9 inhibitors, which lack long-term cardiovascular outcomes data, will be used in place of statins, an established class of drugs with extensive evidence of clinical benefit and long-term safety.


Related Content

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts